Abstract 【Objective】To investigate the efficacy of paclitaxel combined with intensity modulated radiation therapy and its effects on the expression of osteopontin (OPN) and matrix metalloproteinase-9 (MMP-9) in patients with advanced cervical cancer. 【Methods】A total of 118 patients with advanced cervical cancer in our hospital,were divided into the control group and the observation group according to the treatment plan. The control group of 58 cases were treated with intensity modulated radiotherapy + cisplatin; the study group of 60 cases were treated with paclitaxel on the basis of the control group. The short-term efficacy,long-term efficacy and adverse reactions were compared between the two groups,and the expression levels of serum OPN and MMP-9 were detected and compared as well. 【Results】The short-term effective rate of the observation group was 91.67% and that of the control group was 84.48%. However,there was no significant difference between the two groups (P>0.05). After treatment,the expression levels of serum OPN and MMP-9 in the two groups were lower than those before treatment (P<0.05); And the expression levels of serum OPN and MMP-9 in the observation group were lower than those in the control group (P<0.05). There was no significant difference in the incidence of recent adverse reactions between the two groups (P>0.05). The 3-year cumulative survival rate of the observation group was 73.33% (44/60),which was significantly higher than that of the control group 51.72% (30/58),and the Log Rank test results indicated that the overall survival curves of the two groups were significantly different (P<0.05). 【Conclusion】Paclitaxel combined with intensity modulated radiation therapy is effective in the treatment of advanced cervical cancer. It can down-regulate the expression of serum OPN and MMP-9,improve the long-term survival rate,and the safety is acceptable.
ZHANG Jin-tao,MA Xian-ping. Efficacy of Paclitaxel Combined with Intensity Modulated Radiation Therapy on Advanced Cervical Cancer and Expression of Serum OPN and MMP-9[J]. JOURNAL OF CLINICAL RESEARCH, 2022, 39(6): 881-884.
2022, Vol. 39 
